PTCT earnings call for the period ending December 31, 2018.
News & Analysis: PTC Therapeutics
Earnings and some capital moves hurt these stocks.
The company announced the pricing of a share offering announced the day before.
The company's development-stage SMA treatment was supposed to knock out the market leader, but now it may be the one at risk of an upset.
The company's making an acquisition to bulk up its pipeline of clinical-stage drugs.
A new drug could move the needle someday, but competitive risks loom.
PTC Therapeutics shares are spiking following intriguing trial data; however, it's not the only competitor working on better treatments for SMA.
Welcome to biotech investing.
Find out which of these stocks got a buyout bid.
Investors value a new round of data for PTC's spinal muscular atrophy drug.